Continuous peripheral nerve block catheters are gaining traction in the healthcare sector as an effective analgesic for pain management. The global market for continuous peripheral never block catheters (CPNBC) was valued at US$ 372.8 Mn in 2015, and is expected to witness a year-over-year growth of 4.9% to reach US$ 391.2 Mn in 2016.
Increasing prevalence of osteoarthritis and effectiveness of CPNBC in upper/lower extremity joint replacement procedures will continue to fuel growth of the market in 2016. Other factors, such as cost-effectiveness and lower hospital stay are also making continuous peripheral never block catheters an appealing option for analgesia among healthcare professionals. However, longstanding challenges, such as lack of trained professionals and ambiguity over standard usage guidelines are anticipated to pose challenges to widespread adoption.
The U.S. will continue to be at the forefront of adoption of continuous peripheral nerve block catheters, making North America the most lucrative market globally. North America’s revenue share in the global CPNBC market is expected to reach 42.4% in 2016. Western Europe is the second-largest market, with total revenues reaching US$ 61.3 Mn in 2016.
By product, non-stimulating catheter systems account for the highest demand—in 2016, global revenues are anticipated to total US$ 220.8 Mn. On the other hand, the over-the-needle product segment will witness lowest demand in 2016 and beyond.
By insertion technique, ultrasound insertion is gaining traction over nerve stimulation although the latter accounts for the majority revenue share of the market currently. Ultrasound insertion revenues are anticipated to grow by 5.8% in 2016, whereas over nerve stimulation revenues will grow by 4.5%.
By indication, lower extremity surgeries will continue to be the leading segment, accounting for US$ 119.8 Mn in...